- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02088021
Assessment of the St. Jude Medical PorticoTM Re-sheathable Aortic Valve System - Alternative Access (PorticoALTEU)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has provided written informed consent.
- Subject is 65 years of age or older at the time of index procedure, and/or has comorbidities that, in the opinion of the Principal Investigator or the Subject Selection Committee, preclude surgical valve replacement.
- Subject's aortic annulus diameter meets the range indicated in the Instructions for Use as measured by multislice CT conducted within 120 days prior to the index procedure.
Subject has senile degenerative aortic stenosis with echocardiography within 30 days of index procedure as defined by at least 1 of the following:
- derived mean gradient greater than 40 mmHg, OR
- jet velocity greater than 4.0 m/s, OR
- aortic valve area of less than 0.8 cm2, OR
- aortic valve area index less than or equal to 0.6 cm2/m2.
- Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional Classification of II, III, or IV.
- Subject is deemed high operable risk and delivery route is suitable for TAVI per the medical opinion of the Subject Selection Committee.
- Subject's predicted operative mortality or serious, irreversible morbidity risk is less than 50% at 30 days post index procedure.
Exclusion Criteria:
- Subject is unwilling or unable to comply with all study-required follow-up evaluations.
- Subject has a documented history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 6 months (less than or equal to 180 days) prior to the index procedure.
- Subject has carotid artery disease requiring intervention.
- Evidence of an acute myocardial infarction (MI) within 30 days prior to patient providing consent (defined as: ST Segment Elevation as evidenced on 12 Lead ECG).
- Subject has a native aortic valve that is congenitally unicuspid, bicuspid, quadricuspid or non-calcified as seen by echocardiography.
- Subject has mitral valvular regurgitation greater than grade III.
- Subject has moderate or severe mitral stenosis.
- Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in any position.
- Subject refuses any blood product transfusion.
- Subject refuses surgical valve replacement.
- Subject has left ventricular ejection fraction (LVEF) less than 20%.
- Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring revascularization.
- Subject has had a percutaneous interventional or other invasive cardiovascular or peripheral vascular procedure less than or equal to 14 days of index procedure.
- Subject has severe basal septal hypertrophy that would interfere with transcatheter aortic valve placement.
- Subject has a history of, or is currently diagnosed with endocarditis.
- There is imaging evidence of intracardiac mass, thrombus, or vegetation.
- Subject is considered hemodynamically unstable (requiring inotropic support or mechanical heart assistance).
- Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to stabilize heart failure.
- Subject with significant pulmonary disease as determined and documented by the Investigator.
- Subject has significant chronic steroid use as determined and documented by the Investigator.
- Subject has a documented hypersensitivity or contraindication to anticoagulant or antiplatelet medication.
- Subject has renal insufficiency as evidenced by a serum creatinine greater than 3.0 mg/dL (265.5 µmol/L) or end-stage renal disease requiring chronic dialysis.
- Subject has morbid obesity defined as a BMI greater than or equal to 40.
- Subject has ongoing infection or sepsis.
- Subject has blood dyscrasias (eg, leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy).
- Subject has a current autoimmune disease that, in the opinion of the Principal Investigator or the Subject Selection Committee, precludes the subject from study participation.
- Significant ascending aortic disease documented by diameter greater than 40mm.
- Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within 90 days prior to the index procedure.
- Subject is currently participating in another investigational drug or device study.
- Subject requires emergency surgery for any reason.
- Subject has a life expectancy less than 12 months.
- Subject has other medical, social or psychological conditions that, in the opinion of the Principal Investigator or the Subject Selection Committee, preclude the subject from study participation.
- Subject is diagnosed with dementia or admitted to a chronic care facility which would fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits.
- Subject is unwilling or unable to comply with all study-required follow-up evaluations.
- Subject has a documented history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 6 months (less than or equal to 180 days) prior to the index procedure.
- Subject has carotid artery disease requiring intervention.
- Evidence of an acute myocardial infarction (MI) within 30 days prior to patient providing consent (defined as: ST Segment Elevation as evidenced on 12 Lead ECG).
- Subject has a native aortic valve that is congenitally unicuspid, bicuspid, quadricuspid or non-calcified as seen by echocardiography.
- Subject has mitral valvular regurgitation greater than grade III.
- Subject has moderate or severe mitral stenosis.
- Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in any position.
- Subject refuses any blood product transfusion.
- Subject refuses surgical valve replacement.
- Subject has left ventricular ejection fraction (LVEF) less than 20%.
- Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring revascularization.
- Cardiovascular or peripheral vascular procedure less than or equal to 14 days of index procedure.
- Subject has severe basal septal hypertrophy that would interfere with transcatheter aortic valve placement.
- Subject has a history of, or is currently diagnosed with endocarditis.
- There is imaging evidence of intracardiac mass, thrombus, or vegetation.
- Subject is considered hemodynamically unstable (requiring inotropic support or mechanical heart assistance).
- Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to stabilize heart failure.
- Subject with significant pulmonary disease as determined and documented by the Investigator.
- Subject has significant chronic steroid use as determined and documented by the Investigator.
- Subject has a documented hypersensitivity or contraindication to anticoagulant or antiplatelet medication.
- Subject has renal insufficiency as evidenced by a serum creatinine greater than 3.0 mg/dL (265.5 µmol/L) or end-stage renal disease requiring chronic dialysis.
- Subject has morbid obesity defined as a BMI greater than or equal to 40.
- Subject has ongoing infection or sepsis.
- Subject has blood dyscrasias (eg, leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy).
- Significant ascending aortic disease documented by diameter greater than 40mm.
- Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within 90 days prior to the index procedure.
- Subject is currently participating in another investigational drug or device study.
- Subject requires emergency surgery for any reason.
- Subject has a life expectancy less than 12 months.
- Subject has other medical, social or psychological conditions that, in the opinion of the Principal Investigator or the Subject Selection Committee, preclude the subject from study participation.
- Subject is diagnosed with dementia or admitted to a chronic care facility which would fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits.
- Subject has a documented allergy to contrast media, nitinol alloys, porcine tissue, or bovine tissue.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Portico Transcatheter Aortic Valve Implantation
Placement of the SJM Portico aortic valve with a ALC delivery system
|
Placement of the SJM Portico aortic valve with a ALC delivery system
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Major Vascular Complications related to the Portico ALC Delivery System
Time Frame: 30 day post procedure
|
30 day post procedure
|
All cause mortality
Time Frame: 30 day post procedure
|
30 day post procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event Rates
Time Frame: 30 days post procedure
|
Event rates as described by VARC-2 "Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document European Heart Journal (2012) 33, 2403-2418." |
30 days post procedure
|
Functional improvement from baseline
Time Frame: 30 days post procedure
|
Functional improvement from baseline as compared to 30 days by:
|
30 days post procedure
|
Acute device success
Time Frame: 12 months post procedure
|
Acute device success defined as:
|
12 months post procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Axel Linke, Prof Dr. med, Heart Center Leipzig - University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL07045
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Symptomatic Aortic Stenosis
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Andres Iñiguez RomoCompletedSymptomatic Aortic StenosisSpain
-
Keystone HeartCompletedSymptomatic Aortic StenosisUnited States, Netherlands, Germany, Italy
-
Symetis SACompletedSymptomatic Aortic StenosisGermany, Italy, Argentina, Switzerland
-
Second Affiliated Hospital, School of Medicine,...RecruitingSymptomatic Aortic StenosisChina
-
Medtronic CardiovascularActive, not recruitingSymptomatic Aortic StenosisCanada, United States, Sweden, Israel, Germany, Belgium, United Kingdom, Australia, Italy, Ireland, France, Spain
-
Assistance Publique - Hôpitaux de ParisMedtronicCompletedSymptomatic Aortic StenosisFrance
-
Medtronic CardiovascularMedtronicTerminated
-
University Hospital, RouenCompleted
-
P+F Products + Features GmbHMeditrial USA Inc.RecruitingSymptomatic Aortic StenosisSpain, Argentina, Lithuania, Portugal, Brazil, Chile
Clinical Trials on Portico Transcatheter Aortic Valve
-
Abbott Medical DevicesRecruitingAortic Valve StenosisUnited States, Australia
-
Abbott Medical DevicesCompletedAortic Valve StenosisUnited Kingdom, Netherlands, Spain, Germany, Belgium, Australia, Denmark, Canada, Italy, France, Israel, Lithuania, Switzerland
-
Abbott Medical DevicesWithdrawnSevere Symptomatic Aortic StenosisUnited Kingdom
-
Clinique PasteurUnknownBicuspid Aortic ValveFrance
-
Didier TCHETCHEAbbottNot yet recruitingBicuspid Aortic ValveFrance
-
IRCCS Policlinico S. DonatoRecruiting
-
Xijing HospitalRecruitingAortic Valve RegurgitationChina
-
Xijing HospitalRecruiting
-
Xijing HospitalRecruitingAortic Valve Disease MixedChina
-
University of PadovaFondazione GISE OnlusRecruiting